Flextra Joins Elydan Group to Accelerate Its Growth
Flextra, a Finnish company specializing in geothermal systems and hot water distribution in buildings through pre-insulated flexible systems, joins Elydan Group, a European mid-sized enterprise specializing in fluid distribution and management systems.
Flextra will accelerate the Group's presence in Finland and the Baltic countries by providing complementary product ranges tailored to Nordic market requirements. The company is expected to generate more than €3 million in revenue in 2024.
Elydan Group is a European mid-sized enterprise (ETI) specializing in fluid transport and management for a transitioning, decarbonized world. With over 60 years of expertise, Elydan offers a wide range of innovative, low-carbon, sustainable, and recyclable products for the construction and public works industries, operating in two key areas:
- Energy: Hot and cold water distribution, geothermal energy, district heating networks, electrical conduits, ventilation, and gas distribution.
- Environment: Drinking water management, sanitation, irrigation, and plastic recycling (PE and PP).
Today, Elydan Group consists of over 400 employees, €200 million in revenue in 2024, subsidiaries in Germany, Sweden, and Finland, seven production sites in France and Belgium and one recycling center and a presence in 50 countries across four continents.
«Europe has committed to significantly decarbonizing the heating sector, which is the largest emitter of greenhouse gases. Thanks to this merger with Flextra, Elydan Group strengthens its presence in Europe to establish itself as a leading European player in the energy sector. It will help expand our product range but also strengthen our network to support local stakeholders in their energy efficiency projects. Through its energy division, Endralis, Elydan Group aims to play a leading role by offering innovative and sustainable solutions for the construction and public works industries, addressing the challenges of the energy transition »
Marc-Antoine Blin
President of Elydan Group
« Flextra wants to be involved in and support Elydan Group and our shared goals. Flextra sees a company like Elydan as a key player in significantly reducing the carbon footprint.
We also see a great opportunity for growth together with Elydan.»
Ari Rasinkangas
President of Flextra
Team Retention and Integration into the International Board
The company will become a fully integrated subsidiary of Elydan Group while maintaining its existing management teams. The leadership team will join the Group’s international board to actively contribute to its development.
The synergies expected from these acquisitions will enable the Group, its subsidiaries, and its teams to offer a broader range of technical solutions to reseller and installer partners and to develop new connections across Europe and globally.
The Official Presentation of the Energy Division, Endralis,
Will Take Place at ISH, the Largest HVAC Trade Fair in Europe,
in Frankfurt from March 17 to 21, 2025.
About Flextra –https://flextra.fi/
Flextra is one of the fastest-growing building technology sector company in Finland. Flextra focuses on heating and cooling solutions. Flextra also have a wide range of geothermal products.
About Elydan Group – www.elydan.eu
Elydan Group is a European mid-sized enterprise (ETI) specializing in fluid transport and management for a transitioning, decarbonized world.
With over 60 years of expertise, Elydan Group offers a wide range of innovative, low-carbon, sustainable, and recyclable products for the construction and public works industries, operating in two key areas:
- Energy, with Endralis activities: Hot and cold water distribution, geothermal energy, district heating networks, electrical conduits, ventilation, and gas distribution.
- Environment, with Elydan activites: Drinking water management, sanitation, irrigation, and plastic recycling (PE and PP).
Today, Elydan Group consists of:
- Over 400 employees
- €200 million in revenue in 2024
- Subsidiaries in Germany, Sweden, and Finland
- Seven production sites in France and Belgium and one recycling center
- A presence in 50 countries across four continents
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227952573/en/
Contacts
Ari Rasinkangas - +358 40 350 9925
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU ® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy28.2.2025 15:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and pu
Radisys Expands Small Cell Portfolio with Qualcomm Dragonwing FSM200 Platform for FR1 and FR228.2.2025 15:00:00 EET | Press release
Radisys® Corporation, a global leader of open telecom solutions, announced the availability of its award-winning Connect RAN software on the Qualcomm Dragonwing™ FSM200 Platform for both FR1 and FR2. The solution leverages baseband and advanced Radio capabilities of the Dragonwing FSM200 platform to address high performance/capacity use cases with advanced features required in various market segments, including MNOs, enterprise, Fixed Wireless Access (FWA), private 5G, Industry 4.0 and home networks. Radisys Connect RAN software on the Qualcomm Dragonwing™ FSM100 platform is already globally deployed for various use cases. Radisys' Connect RAN 5G solution offers a comprehensive feature set, fully interoperable with a wide ecosystem and robust manageability support, enabling customers to deploy small cells in multiple verticals at reduced operational and capital expenses with a quick time-to-market. Highlights Radisys demonstrated continued leadership in mmWave RAN on Dragonwing FSM100
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO ® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations28.2.2025 14:22:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We are thrilled by the positive CHMP opinion in support of expanding the KAFTRIO in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said Fosca De Iorio, M.D., Vice President, International Medical Affairs at Vertex. “If approved, thousands of additional patients across Europe will be eligible for a CFTR modulator, bringing us closer than ever to our goal of getting treatments that address the underlying cause of the disease to all people living with CF.” In the Eur
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order28.2.2025 14:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company’s Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order. As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement (the “Exchange Shares”), including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled. The
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax28.2.2025 13:21:00 EET | Press release
Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the Phase II portion of the trial for efficacy testing as of today, on 28th Feb., 2025. We are pleased to inform that we already have multiple potential patients waiting to participate in the trial. Please take notice of our own innovative approach for miserable cancer patients and contact us. View source version on businesswire.com: https://www.businesswire.com/news/home/20250228414852/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom